Xeriant, Inc. filings document public-company reporting, material agreements, and capital-structure matters for the OTCQB issuer. Recent records include Form 8-K disclosure of a settlement agreement related to a senior secured promissory note, including common-stock conversion shares, warrant treatment, payment obligations, and related litigation-proceeds provisions.
The company’s Form 12b-25 filing records a late Form 10-Q notification and the reporting-status disclosures associated with periodic financial statements. Xeriant’s filings also identify its Nevada incorporation, common-stock reporting context, and the absence of securities registered on a national exchange under Section 12(b).
Xeriant, Inc. (XERI) reported net income of $392,278 for the year ended June 30, 2026, compared with a net loss of $1,646,898 in fiscal 2025. Fiscal 2026 income included a $2,810,278 gain on extinguishment of debt.
Operating activities used $791,756 of cash, compared with $1,288,505 in fiscal 2025. Cash was $87,594 and the working capital deficit was $4,897,313 at June 30, 2026. Management estimated available cash would last approximately four months from that date, and management and the auditor stated substantial doubt about Xeriant’s ability to continue as a going concern. Xeriant recorded a $3,500,000 Auctus settlement liability and reported no cash payments under the settlement as of June 30, 2026; settlement terms were extended through October 31, 2026.
Xeriant remains a development-stage company with no sales. It reported completing 16 NexBoard certification tests as of the report date, and its patent covering proprietary technology was issued July 14, 2026.
Xeriant, Inc. reported net income of $1.93 million for the six months ended December 31, 2025, reversing a prior-year loss. This was driven almost entirely by a $2.74 million gain on extinguishment of debt from a settlement restructuring a senior secured note with Auctus Fund, while the core business recorded a $0.54 million operating loss.
The balance sheet remains very weak, with only $76,533 in cash, total assets of $103,440, and total liabilities of $5.74 million, resulting in a stockholders’ deficit of $5.64 million. Current liabilities include a $3.5 million settlement liability and $1.67 million of convertible notes payable, net of discount. The company also has a large potential overhang from warrants, options, preferred stock and convertible debt.
Management discloses that recurring losses, an accumulated deficit of $26.41 million, and a working capital deficit of $5.65 million raise substantial doubt about Xeriant’s ability to continue as a going concern. Based on its historical spending, the company expects its cash to last about two months from February 17, 2026, and plans to seek additional debt or equity financing while pursuing commercialization of its NEXBOARD™ advanced materials product.
Xeriant, Inc. reported quarterly results for the three months ended September 30, 2025, showing net income of $2,226,072 driven largely by a $2,743,546 gain on extinguishment of debt from a settlement of its senior secured note with Auctus Fund. Operating activities still produced a loss of $304,075 as the company continues to invest in consulting, R&D and professional fees while generating no disclosed revenue.
At September 30, 2025, Xeriant had cash of $52,136, total assets of $71,730 and a stockholders’ deficit of $5,702,498, including a working capital deficit of $5,710,579. Management states there is substantial doubt about the company’s ability to continue as a going concern and estimates existing cash would last about two months from mid-November 2025 without new funding. The company is pursuing additional capital via equity and debt while advancing its DUREVER and NEXBOARD advanced materials portfolio and maintaining an ongoing lawsuit against XTI Aircraft Company.
Xeriant, Inc. filed a Form 12b-25 (NT 10-Q) notifying a late filing for its quarterly report for the period ended September 30, 2025. The company states it cannot file within the prescribed time without unreasonable effort and expense.
Xeriant cites the need for additional time to complete the presentation of certain information in its financial statements and related notes and to compile supporting documentation. The company expects to file the Form 10-Q no later than the fifth calendar day after the prescribed due date.
Xeriant, Inc. entered into a Settlement Agreement with Auctus Fund tied to a prior senior secured promissory note. The agreement, effective retroactive to October 29, 2025, includes issuing 30,000,000 unrestricted common shares to Auctus pursuant to a February 24, 2025 conversion notice and a commitment for cash payments totaling $3,500,000.
Cash installments are scheduled as follows: $1,000,000 on or before 75 days from October 29, 2025; $1,000,000 on or before 105 days; $1,000,000 on or before 135 days; and $500,000 on or before 165 days. Auctus will suspend further conversions under the note so long as payments are made. If payments are timely, Auctus will return two warrants (each for 25,000,000 shares); Auctus retains an original warrant for 50,968,828 shares. The company will share any proceeds it receives from its legal action against XTI Aircraft Company on a preferred basis, net of legal fees capped at $250,000. The 30,000,000 shares are being issued under Section 4(a)(2) of the Securities Act. A leak-out agreement governs Auctus’s sales of received stock.
Xeriant, Inc. reports significant liquidity and capital structure issues while advancing a new product initiative. The company had a $8,708,900 working capital deficit and notes that, based on historical spending, it expects to expend available cash in approximately three months from October 2, 2025, creating substantial doubt about its ability to continue as a going concern. The filing discloses 749,053,035 outstanding common shares and extensive convertible instruments: warrants totaling roughly 111,568,828 and 118,968,828 outstanding in different series and multiple convertible notes with low conversion prices and adjustment features. The company is developing NEXBOARD, a wallboard product that requires industry certification, and appointed two senior advisors in nanomaterials. Significant financing arrangements include a note from Auctus with conversion activity and related legal dispute, plus outstanding notes with conversion at $0.01 per share.